MAT Biopharma today announced the
initiation of an escalating-dose Phase I/II study of the Company’s antibody
Ferritarg P(R) in patients with relapsed or refractory Hodgkin’s disease.
The study conducted in collaboration with Institut Curie will seek to
enroll around 20 patients.
The goal of this study is to evaluate pharmacokinetic, the safety and
the maximum tolerated dose (MTD) of Ferritarg P(R) in patients with
Hodgkin’s disease.
In July 2006, FDA granted Orphan Drug Designation to MAT Biopharma’s
Ferritarg P(R). This was an important step for MAT Biopharma’s ongoing
effort to provide a new therapeutic option to patients afflicted by this
disease.
“The initiation of this trial is an important milestone in the
development of Ferritarg P(R) and has the potential to be a significant
driver of the company’s future growth,” said Jean Kadouche, Chief Executive
Officer.
About Hodgkin’s disease
Hodgkin’s disease, also known as Hodgkin’s lymphoma, is a rare cancer
of the lymphatic system. In Hodgkin’s disease, cells in the lymphatic
system grow abnormally and may spread beyond the lymphatic system. As
Hodgkin’s disease progresses, it compromises your body’s ability to fight
infection.
Hodgkin’s disease most commonly affects people between the ages of 20
and 30 and people older than age 75. It’s one of two common types of
cancers of the lymphatic system. According the American Cancer Society, in
the United States in 2004, there were about 7,880 new cases of Hodgkin’s
disease.
About MAT Biopharma.
MAT Biopharma is a privately held biopharmaceutical company focused on
the development and commercialization of antibody based therapeutics for
the treatment of haematological cancers and some solid tumors.
MAT Biopharma
matbiopharma.fr